Abstract
p53 antibodies have been found in the sera of patients with various types of cancer. The presence of these antibodies is generally associated with p53 accumulation in the tumour that is believed to trigger this humoral response. The recent discovery of 2 new members of the p53 family, p73 and p63, led us to study the specificity of this immune response towards the 3 proteins. Serum samples from 148 patients with various types of cancer were tested for antibodies against p73 and p63 using immunoprecipitation. 72 patients were previously shown to have p53 antibodies whereas 76 were negative. The control group consisted of 50 blood donors. p73 were detected in 22/148 (14.9%) of the cancer patients (11/72 in the group with p53-antibodies and 11/76 in the negative group). Only two sera from the control (4%) were positive. p63 antibodies were detected in only 4/148 (2.7%) of the cancer patients. Epitope mappings were performed and demonstrate that p73 antibodies are directed toward the central region of the p73 protein whereas p53 antibodies react predominantly toward the amino- and the carboxy-terminus of p53. Our results indicate that there is a specific immune response toward the p73 protein in cancer patients, a finding supported by an increasing number of publications describing p73 accumulation in tumoral cells. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bartek J, Bartkova J, Lukas J, Staskova Z, Vojtesek B and Lane DP (1993) Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol 169: 27–34
Bjork-Eriksson T, West CML and Cvetskovska E (1999) The expression of p73 is increased in lung cancer, independent of p53 gene alteration. Brit J Cancer 80: 1623–1629
Cai YC, Yang G and Nie Y (2000) Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. Carcinogenesis 21: 683–689
Crawford LV, Pim DC and Bulbrook RD (1982) Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30: 403–408
Hammel P, Boissier B and Chaumette MT (1997) Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 40: 356–361
Hardy-Bessard AC, Garay E and Lacronique V (1998) Regulation of the specific DNA binding activity of Xenopus laevis p53: evidence for conserved regulation through the carboxy-terminus of the protein. Oncogene 16: 883–890
Herath NI, Kew MC and Whitehall VL (2000) p73 is up-regulated in a subset of hepatocellular carcinomas. Hepatology 31: 601–605
Ikawa S, Nakagawara A and Ikawa Y (1999) p53 family genes: structural comparison, expression and mutation [see comments]. Cell Death Differ 6: 1154–1161
Kaghad M, Bonnet H and Yang A (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809–819
Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ and Pavletich NP (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948–953
Lee LA, Walsh P and Prater CA (1999) Characterization of an autoantigen associated with chronic ulcerative stomatitis: the CUSP autoantigen is a member of the p53 family. J Invest Dermatol 113: 146–151
Legros Y, Lacabanne V, D'Agay MF, Larsen CJ, Pla M and Soussi T (1993) Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. Bull. du Cancer 80: 102–110
Legros Y, Lafon C and Soussi T (1994a) Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. Oncogene 9: 2071–2076
Legros Y, Meyer A, Ory K and Soussi T (1994b) Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein. Oncogene 9: 3689–3694
Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323–331
Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY and Melino G (2000) The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 113: 1661–1670
Loiseau H, Arsaut J and Demotes-Mainard J (1999) p73 gene transcripts in human brain tumors: overexpression and altered splicing in ependymomas. Neurosci Lett 263: 173–176
Lubin R, Schlichtholz B and Bengoufa D (1993) Analysis of p53 antibodies in patients with various cancers define B-Cell epitopes of human p53 – distribution on primary structure and exposure on protein surface. Cancer Res 53: 5872–5876
Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild C and Soussi T (1995) p53 antibodies in patients with various types of cancer: assay, identification and characterization. Clinical Cancer Res 1: 1463–1469
MacCallum DE and Hupp TR (1999) Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res 59: 3257–3263
Marin MC and Kaelin WG (2000) p63 and p73: old members of a new family. Biochim Biophys Acta 1470: M93–M100
Marin MC, Jost CA, Irwin MS, DeCaprio JA, Caput D and Kaelin WG, Jr (1998) Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol 18: 6316–6324
Ng SW, Yiu GK, Liu Y, Huang LW, Palnati M, Jun SH, Berkowitz RS and Mok SC (2000) Analysis of p73 in human borderline and invasive ovarian tumor. Oncogene 19: 1885–1890
Ory K, Legros Y, Auguin C and Soussi T (1994) Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 13: 3496–3504
Peters UR, Tschan MP and Kreuzer KA (1999) Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis. Cancer Res 59: 4233–4236
Polge A, Bourgaux JF and Bancel E (1998) p53 and follow-up of colorectal adenocarcinomas. Dig Dis Sci 43: 1434–1442
Portefaix JM, Thébault S and Bourgain-Guglielmetti F (2000) Critical residues of epitopes recognized by several anti-p53 monoclonal antibodies correspond to key residues of p53 involved in interaction with the mdm2 protein. J Imm Methods,
Scherr DS (1999) Expression of p73 and Its relation to histopathology and prognosis in hepatocellular carcinoma. J Nat Cancer Inst 91: 1154–1158
Schlichtholz B, Tredaniel J, Lubin R, Zalcman G, Hirsch A and Soussi T (1994) Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 69: 809–816
Soussi T (2000) p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60: 1777–1788
Soussi T, Dehouche K and Béroud C (2000) p53 Website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis. Hum Mutat 15: 105–113
Takada N, Ozaki T, Ichimiya S, Todo S and Nakagawara A (1999) Elevated and biallelic expression of p73 is associated with progression of human bladder cancer. Cancer Res 59: 2791–2793
Tannapfel A, Engeland K, Weinans L, Katalinic A, Hauss J, Mossner J and Wittekind C (1999) Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. Brit J Cancer 80: 1069–1074
Trink B, Okami K, Wu L, Sriuranpong V, Jen J and Sidransky D (1998) A new human p53 homologue. Nature Med 4: 747–748
Vennegoor C, Nijman HW and Drijfhout JW (1997) Autoantibodies to p53 in ovarian cancer patients and healthy women: A comparison between whole p53 protein and 18-mer peptides for screening purposes. Cancer Lett 116: 93–101
Vojtesek B, Bartek J, Midgley CA and Lane DP (1992) An immunochemical analysis of the human nuclear phosphoprotein-p53 – new monoclonal antibodies and epitope mapping using recombinant-p53. J Immunol Methods 151: 237–244
Vojtesek B, Dolezalova H and Lauerova L (1995) Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene 10: 389–393
Yokomizo A, Mai M and Tindall DJ (1999) Overexpression of the wild type p73 gene in human bladder cancer. Oncogene 18: 1629–1633
Zalcman G, Schlichtholz B and Trédaniel J (1998) Monitoring of p53 auto antibodies in lung cancer during therapy: relationship to response to treatment. Clin. Cancer Res 4: 1359–1366
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Tominaga, O., Unsal, K., Zalcman, G. et al. Detection of p73 antibodies in patients with various types of cancer: immunological characterization. Br J Cancer 84, 57–63 (2001). https://doi.org/10.1054/bjoc.2000.1542
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2000.1542
Keywords
This article is cited by
-
The specific seroreactivity to ∆Np73 isoforms shows higher diagnostic ability in colorectal cancer patients than the canonical p73 protein
Scientific Reports (2019)
-
The role of p73 in hematological malignancies
Leukemia (2006)
-
Monoclonal antibodies raised against Xenopus p53 interact with human p73
Oncogene (2002)
